Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical Trial

NCT02839642 is registered in ClinicalTrials.gov with Assistance Publique Hopitaux De Marseille as lead sponsor.

NCT NCT02839642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02839642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical Trial
Lead sponsor
Assistance Publique Hopitaux De Marseille
Phase
Phase 3
Overall status
Completed
Start date
July 26, 2016
Completion date
November 17, 2022
Enrollment
106 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

progressive supranuclear palsy (psp)